Mihály Tapolyai

Summary

Publications

  1. ncbi r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline
    Mihály Tapolyai
    Department of Nephrology and Hypertension, Cleveland Clinic Florida, USA
    BMC Nephrol 4:3. 2003
  2. ncbi Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control
    Mihály Tapolyai
    Department of Nephrology, Louisiana State University Health Science Center Shreveport, 1501 Kings Highway, Shreveport, LA 71130, USA
    J Clin Hypertens (Greenwich) 10:215-8. 2008
  3. ncbi B-type natriuretic peptide-directed ultrafiltration improves care in acutely hospitalized dialysis patients
    Mihály Tapolyai
    Division of Nephrology and Hypertension, Department of Medicine, Louisiana State University Health Sciences Center, 501 Kings Highway, Shreveport, LA, USA
    Congest Heart Fail 15:131-5. 2009
  4. ncbi Regional differences in nonadherence to dialysis among southern dialysis patients: a comparative cross-sectional study to the dialysis outcomes and practice patterns study
    Mihály Tapolyai
    Department of Internal Medicine, Louisiana State University Health Sciences Center Shreveport, USA
    Am J Med Sci 339:516-8. 2010
  5. ncbi Dialysis patients' fluid overload, antihypertensive medications, and obesity
    Mihály Tapolyai
    Fresenius Dialysis Center, Semmelweis University, Budapest, Hungary
    ASAIO J 57:511-5. 2011
  6. ncbi High prevalence of liddle syndrome phenotype among hypertensive US Veterans in Northwest Louisiana
    Mihály Tapolyai
    Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA
    J Clin Hypertens (Greenwich) 12:856-60. 2010
  7. ncbi Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning
    Mihály Tapolyai
    Cleveland Clinic Florida, Fort Lauderdale, FL 33309, USA
    Nephron 90:213-5. 2002

Detail Information

Publications7

  1. ncbi r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline
    Mihály Tapolyai
    Department of Nephrology and Hypertension, Cleveland Clinic Florida, USA
    BMC Nephrol 4:3. 2003
    ..As EPO treatment of chronic anemia of advanced renal disease is now the standard of care we examined if such treatment may slow the progression of renal function decline...
  2. ncbi Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control
    Mihály Tapolyai
    Department of Nephrology, Louisiana State University Health Science Center Shreveport, 1501 Kings Highway, Shreveport, LA 71130, USA
    J Clin Hypertens (Greenwich) 10:215-8. 2008
    ..4, 106.4, and 115.4 mm Hg (P=.002). The authors conclude that in this group of primarily African American patients, the control of hypertension in ESRD is not achieved by escalating the number of antihypertensive medications...
  3. ncbi B-type natriuretic peptide-directed ultrafiltration improves care in acutely hospitalized dialysis patients
    Mihály Tapolyai
    Division of Nephrology and Hypertension, Department of Medicine, Louisiana State University Health Sciences Center, 501 Kings Highway, Shreveport, LA, USA
    Congest Heart Fail 15:131-5. 2009
    ....
  4. ncbi Regional differences in nonadherence to dialysis among southern dialysis patients: a comparative cross-sectional study to the dialysis outcomes and practice patterns study
    Mihály Tapolyai
    Department of Internal Medicine, Louisiana State University Health Sciences Center Shreveport, USA
    Am J Med Sci 339:516-8. 2010
    ..Southern networks continue to have higher degrees of adverse outcomes despite improvements in healthcare delivery...
  5. ncbi Dialysis patients' fluid overload, antihypertensive medications, and obesity
    Mihály Tapolyai
    Fresenius Dialysis Center, Semmelweis University, Budapest, Hungary
    ASAIO J 57:511-5. 2011
    ..01). Overhydration is strongly associated with the use of antihypertensive medications and the use of diuretics in this dialysis population. Obesity seems to afford some protection from OH...
  6. ncbi High prevalence of liddle syndrome phenotype among hypertensive US Veterans in Northwest Louisiana
    Mihály Tapolyai
    Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA
    J Clin Hypertens (Greenwich) 12:856-60. 2010
    ..In this hypothesis-generating study, the authors detected an unusually high prevalence of biochemical abnormalities compatible with likely LS syndrome from Northwestern Louisiana, approaching that of likely PHA...
  7. ncbi Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning
    Mihály Tapolyai
    Cleveland Clinic Florida, Fort Lauderdale, FL 33309, USA
    Nephron 90:213-5. 2002
    ..Four hours later he also had a 3-hour CHP which further reduced his CBZ level by 25.3%. Therefore we conclude that HD with high-flux dialyzers is at least as effective as CHP for the removal of CBZ from the blood after CBZ intoxication...